AGILENT TECHNOLOGIES INC 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: Agilent delivered a strong Q3 FY2026 with revenue of $1.88 billion, up 7.3% core and 8.1% reported. Non-GAAP operating margin was 27.2% ex tariff refunds (28.3% including them), up 210 bps year over year ex refunds. EPS was $1.56 ex refunds, up 14% YoY and $0.06 above guidance high end; reported EPS was $1.62. Gross margin improved to 54.9% ex refunds. Free cash flow was $439 million with 96% conversion, and net leverage remained low at 1.0x.

Company Outlook & Strategy: Management raised full-year FY2026 core growth guidance to 5.8%–6.0% and EPS guidance to $6.18–$6.21, implying about 10% EPS growth ex tariff refunds. Operating margin expansion is now expected to exceed 100 bps ex refunds. The company emphasized its Ignite Operating System, pricing discipline, commercial execution, innovation, and operational efficiency as key drivers. Management sees strong momentum into Q4 and expects meaningful pharma reshoring revenue contributions in fiscal 2027 and beyond.

Key Industry Trends: End markets are improving broadly, especially pharma, China, and applied markets. Pharma grew 12%, supported by better biotech funding and GLP-1 demand. China rebounded strongly, up 9%, despite limited stimulus impact. Applied markets, especially advanced materials and semiconductor-related demand, benefited from AI infrastructure build-out and semiconductor reshoring. PFAS testing demand and food testing activity also remained strong.

Operational Highlights: Instrument revenue grew high single digits, with LC revenue up low double digits and GC revenue up low single digits. Book-to-bill stayed above 1 for the 10th straight quarter. New product launches, including the 9500 Triple Quad ICP-MS, flagship GC systems, Altura columns, Omnis pathology platform, and Raman Insight security products, all gained traction. The Biocare acquisition closed and contributed $10 million in Q3. Train C in CDMO remains on track for spring startup, with most of its initial capacity already booked.

Challenges & Risks: Management cited ongoing inflationary pressure, rising material costs, supply chain headwinds, and geopolitical disruption. The Middle East conflict and weak memory-chip demand are pressuring costs, though Ignite is helping offset them. Europe was softer than other regions, and diagnostics came in slightly below expectations despite strong order growth. CDMO growth in Q4 is expected to be flattish due to customer timing and tough comparisons.

Key Analyst Questions & Responses: Analysts focused on CDMO visibility, margin outlook, China strength, reshoring, and the durability of pharma growth. Management said CDMO still supports a mid-teens long-term growth view, with Train C largely booked and ramping over the next 6–8 quarters. On reshoring, Agilent estimates a ~$1 billion market opportunity through 2030 and expects at least one-third share, with instrument and service revenue mostly incremental. On margins, management remained constructive but declined to guide 2027, saying Ignite and pricing give them confidence in continued strong margin performance. On China, executives attributed strength to pharma, food, biotech, and advanced materials rather than stimulus.